Exon 20 insertions (Ex20Ins) account for 5–7% of EGFR-mutated NSCLC and are a major mechanism of intrinsic resistance to EGFR TKIs, representing a distinct NSCLC subgroup. Here, EGFR is linked to non-small cell lung carcinoma.